A Study of Humoral Immune Response to Inactivated COVID-19 Vaccine in Patients with Psoriasis Receiving Biologics and Small Molecules

Coronavirus disease 2019 (COVID-19) has become a global public health problem due to its rapid transmission and high infection rate.A crucial defense against SARS-CoV-2 infection is vaccination, which is mostly accomplished by generating protective antibodies. 1 Biologics and small molecule medications have been developed recently to give patients with psoriasis new alternatives. 2COVID-19 vaccine was safe and effective for patients with psoriasis who were receiving biologics. 3Tyrosine kinase 2 inhibitors (TYK2i) are presently employed as a novel small molecule medicine targeting TYK2 to intervene in the release of psoriasis-associated inflammatory factors; however, the majority of current data focus on clinical trials evaluating its application in the treatment of psoriasis. 4Evidence on its effect on the immune response of patients following vaccination is lacking.By recognizing the Spike protein of SARS-CoV-2, neutralizing antibodies (NAbs) specifically target the receptor-binding domain (RBD) of Spike protein and block its binding to angiotensin-converting enzyme 2 (ACE2), thereby preventing the virus from entering host cells and preventing infection. 5In order to investigate the impact of systemic treatments on the humoral immune response following COVID-19 vaccination in patients with psoriasis, we measured the concentrations of SARS-CoV-2 NAbs.We recruited patients from the Department of Dermatology.Participants were excluded from having a history of exposure to or infection with COVID-19, and SARS-CoV-2 infection was excluded using PCR testing.This study was approved by the ethics committee of The First Affiliated Hospital of Chongqing Medical University,